



Special Issue:

**ICMS 2025****Master of Management Postgraduate Program**

Jl. Raya Puspittek, Buaran, Pamulang District, South Tangerang City, Banten 15310,

Email: [humanismanajemen@gmail.com](mailto:humanismanajemen@gmail.com)

Website. :

<http://www.openjournal.unpam.ac.id/index.php/SNH>

---

## B2B Marketing Strategies In Improving The Quality Of Drug Sales: Case Studies On Healthcare Providers And Pharmaceutical Manufacturers

**Yuliar Ageng Bintari 1); Muhammad Agratha Friezsanda 2); Oscar Airlangga 3)**1-3Pamulang University, E- Mail : [yuliarageng@gmail.com](mailto:yuliarageng@gmail.com); [fm.agratha@gmail.com](mailto:fm.agratha@gmail.com);  
[Oscar.airlangga.oa@gmail.com](mailto:Oscar.airlangga.oa@gmail.com);

**Abstract:** Drug quality management is a decisive factor in the success of the modern pharmaceutical industry. In the context of Business-to-Business (B2B) marketing, product quality is not merely about meeting regulatory standards; it also serves as a core strategy for building trust, reputation, and loyalty among institutional partners. This study aims to analyze the role and influence of drug quality management on the effectiveness of B2B marketing strategies between pharmaceutical manufacturers and healthcare providers. A qualitative case-study approach was employed through in-depth interviews, observations, and analysis of quality documents. The findings indicate that integrating a GMP-based quality system with a relational marketing approach produces mutually beneficial, long-term partnerships. Practical implications show that quality-oriented B2B marketing strategies enhance competitiveness and business sustainability for Indonesia's pharmaceutical sector.

**Keywords:** Drug quality management, B2B marketing, pharmaceutical industry, institutional trust, GMP.

### INTRODUCTION

The pharmaceutical industry is a strategic sector that relies heavily on trust and product quality. In B2B markets—where transactions occur between pharmaceutical companies and healthcare institutions (hospitals, pharmacies, distributors, large clinics)—drug quality becomes the primary benchmark of partnership success. Over the last two decades, Total Quality Management (TQM) has become an integral component of pharmaceutical business strategy. Manufacturers that maintain consistent quality and comply with regulations such as Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), and Quality Assurance (QA) tend to be more trusted by institutional partners.2. Literature Review.

### LITERATURE

#### 2.1 Quality Management Concepts

According to Juran (2019), quality management encompasses managerial activities that determine policies, goals, and responsibilities related to quality, and implements them through

planning, control, and continuous improvement. In the pharmaceutical context, quality management consists of three main pillars: Good Manufacturing Practice (GMP), Quality Control (QC), and Quality Assurance (QA).

1. Good Manufacturing Practice (GMP) — ensures that products are manufactured consistently in accordance with quality standards.
2. Quality Control (QC) — laboratory testing of raw materials, processes, and finished products.
3. Quality Assurance (QA) — ensures the entire quality system is comprehensively implemented and properly documented.

## 2.2 Total Quality Management (TQM)

As proposed by Deming (1986), TQM emphasizes organization-wide involvement to achieve continuous quality improvement. In pharmaceutical settings, TQM implementation reduces production errors, increases efficiency, and strengthens trust among B2B customers.

## 2.3 B2B Marketing in the Pharmaceutical Sector

Kotler and Keller (2020) argue that B2B marketing focuses on long-term, value-driven relationships rather than one-off transactions. In the pharmaceutical context, this includes:

- Offering stable, proven quality
- Providing technical support and medical education
- Ensuring information transparency and regulatory compliance
- Reliable logistics and distribution capabilities

## 2.4 The Link Between Quality and Institutional Loyalty

Rahmawati (2022) shows that quality directly drives loyalty in healthcare institutions. High-quality medicines create trust-based relationships in which hospitals are more likely to extend contracts and become exclusive partners.

## 2.5 Conceptual Model

Drug Quality Management → Institutional Trust → Partner Loyalty → Success of B2B Marketing Strategies

## RESEARCH METHODOLOGY

### Type and Approach

This research adopts a descriptive qualitative approach using a case-study method. The method was chosen to gain an in-depth understanding of how drug quality management is implemented by pharmaceutical manufacturers and how it affects B2B marketing strategies toward healthcare institutions (such as hospitals and large clinics). The qualitative approach was preferred because it focuses not on numbers but on meanings, processes, and the experiences of industry actors in building quality-based business relationships.

### Location and Subjects

The study was conducted at:

- 1) A national pharmaceutical company with CPOB and ISO 9001 certification.
- 2) Two healthcare providers (one public hospital and one private hospital) that serve as the company's business partners.

Research subjects included:

- Quality Assurance Manager
- B2B Marketing Manager
- Hospital Pharmacist (procurement lead)
- Procurement administrative staff (hospital)

### Types and Sources of Data

Primary Data: obtained through in-depth interviews, field observations, and direct documentation. The focus was on perceptions, experiences, and strategies in maintaining quality and building B2B partnerships.

Secondary Data: obtained from company documents such as GMP, ISO 9001, and CPOB certificates; internal quality audit reports; customer complaint reports; drug procurement contracts; and scientific literature and BPOM/WHO regulations.

### Data Collection Techniques

Three techniques were used: in-depth interviews, observation, and documentation study.

- In-depth Interviews: Conducted with key informants (managers, pharmacists, QA staff) using semi-structured guides to explore quality system implementation, B2B partners' perceptions of drug quality, and quality-based marketing strategies.
- Observation: The researcher observed production processes, quality documentation systems, and interactions between manufacturers and hospitals to verify interview data.
- Documentation Study: Analysis of quality reports, internal audit results, certifications, and cooperation contracts with hospitals.

### Data Analysis Techniques

Data were analyzed using Miles and Huberman's (1994) model consisting of three stages:

- 1) Data Reduction — selecting important data from interviews, observations, and documents, grouped into themes such as "quality implementation," "marketing strategies," and "B2B trust relationships."
- 2) Data Display — presenting data narratively, with tables of findings and matrices of inter-concept relationships.
- 3) Conclusion Drawing/Verification — deriving meaning from the organized data and verifying the consistency across sources. The final outcome is a model linking drug quality management with the effectiveness of B2B strategies.

### Data Validity

To ensure reliability and validity, the following techniques were used: source triangulation (comparing data across informants), method triangulation (cross-checking interview findings with observations and documents), member checks (confirming interpretations with informants), and an audit trail (archiving raw evidence for traceability).

### Research Stages

- Preliminary study: literature review and selection of case-study sites.
- Permits and coordination: research permissions for the company and partner hospitals.
- Field data collection: interviews, observations, documentation.
- Data analysis and interpretation.
- Report writing and verification.

### Conceptual Framework

Drug Quality Management → Institutional Partner Trust → Loyalty & Continuity of B2B Contracts  
→ Success of B2B Marketing Strategies

### Methodological Conclusion

This descriptive qualitative method enables the researcher to understand the strategic meaning of quality management not only as a technical system but also as a marketing tool and a foundation for long-term trust between pharmaceutical manufacturers and healthcare institutions.

## FINDINGS AND DISCUSSION

### 4.1 Overview of Pharmaceutical Quality Implementation

The pharmaceutical industry has a unique characteristic compared to other manufacturing sectors — the quality of its products directly affects human health and safety. Therefore, the implementation of quality management systems in pharmaceutical companies is not only a business necessity but also a moral and regulatory obligation.

From the interviews conducted with the Quality Assurance Manager and B2B Marketing Manager, it was found that the company applies a Good Manufacturing Practice (GMP)-based system supported by ISO 9001:2015 certification. Every process, from raw material procurement

to product distribution, is controlled through Standard Operating Procedures (SOPs), regular audits, and documentation of quality performance indicators.

The quality control process is carried out at three levels:

1. Incoming Material Control — raw materials are tested for purity and safety before entering production.
2. In-Process Control — production is monitored in real time to ensure consistency.
3. Finished Product Testing — the final product is checked for stability, potency, and microbiological safety before release.

Furthermore, the company performs internal audits every six months and external audits annually to ensure the system's compliance with CPOB (Cara Pembuatan Obat yang Baik) and WHO-GMP standards. Any deviation or nonconformity is documented through a Corrective and Preventive Action (CAPA) system.

Respondents emphasized that the integration between the Quality Department and the Marketing Department plays a crucial role in B2B success. Quality performance data (such as complaint rates, product recall history, and audit scores) are used by the marketing team to strengthen the company's credibility in front of hospitals and distributors.

As stated by the QA Manager:

“Quality is not just compliance; it is our reputation. Our B2B partners trust us because we show proof — data, audits, and transparency.”

This finding reinforces that quality management in the pharmaceutical industry functions not only as an internal operational system but also as a strategic marketing instrument that builds credibility and trust among institutional partners.

## 4.2 Relationship Between Quality and B2B Trust

Trust is the foundation of long-term relationships in Business-to-Business (B2B) markets. In the pharmaceutical industry, trust is not built solely through interpersonal communication or branding — it emerges from consistency in product quality and regulatory compliance.

From the interviews with hospital procurement officers, it was revealed that trust toward a pharmaceutical supplier grows from the company's ability to maintain stable quality over time.

The hospital's main considerations when deciding to continue or terminate a contract are:

1. The frequency of product complaints,
2. Timeliness and transparency of responses to issues, and
3. The supplier's compliance with procurement and distribution procedures.

One respondent from a public hospital stated:

“We don't choose suppliers based on price alone. What matters more is whether their products are consistent, safe, and always available when needed.”

This shows that in the B2B context, trust operates as a risk-reduction mechanism. Hospitals and distributors rely on the supplier's integrity because any defect or inconsistency in medicine quality can have serious consequences, including risks to patient safety and hospital reputation.

The study also found that the quality performance indicators (such as zero recalls, clean audit records, and certified manufacturing processes) become trust signals in the B2B relationship. These indicators allow pharmaceutical companies to position themselves as reliable strategic partners rather than mere suppliers.

Furthermore, the interaction between marketing and quality assurance teams forms a continuous feedback loop. When the QA team provides transparent reports on quality performance, the marketing team can confidently communicate these data points to clients, building trust through facts rather than persuasion.

In summary, the research findings highlight that trust in B2B pharmaceutical marketing is an outcome of consistent quality performance, not just relational closeness or sales effort.

## 4.3 Quality as a Marketing Differentiator

In a highly competitive pharmaceutical market, many companies produce similar drugs with equivalent formulations. As a result, product quality becomes a critical differentiator that distinguishes one brand from another.

Based on interviews with the company's B2B marketing manager, it was found that the company positions its quality management system as a marketing advantage rather than a mere compliance requirement. They frequently use their GMP and ISO certifications in promotional materials, hospital presentations, and business tenders to emphasize reliability and safety.

For example, in hospital procurement presentations, the marketing team highlights several aspects of the company's quality performance:

1. Zero product recalls in the past five years.
2. 98% on-time delivery rate to hospital partners.
3. Compliance score of 100% from the most recent internal audit.
4. Use of international-grade raw materials sourced from certified suppliers.

These facts demonstrate that quality is used as a brand-building strategy to enhance the company's reputation and strengthen client loyalty.

The marketing manager stated:

"We do not compete on price. We sell assurance — hospitals buy trust when they buy our products."

This statement illustrates that pharmaceutical B2B marketing in Indonesia is gradually shifting from transactional orientation (price and promotion) to relationship and credibility orientation (trust and quality). The integration between quality and marketing is evident in how both departments collaborate in preparing tender documents and proposals. The QA team ensures data accuracy, while marketing tailors it into persuasive yet factual messaging.

In short, the company successfully transforms technical quality performance into marketable credibility, proving that quality management can serve as a strong competitive differentiator in B2B contexts.

## 4.4 Case Insights

The case study provides several practical insights regarding how pharmaceutical quality management affects the sustainability of B2B relationships.

### 1. Quality performance as a partnership enabler

In both the public and private hospitals studied, decisions to renew cooperation agreements were influenced by how well the pharmaceutical company maintained its product quality. The private hospital even included a clause stating that only products from suppliers with Good Manufacturing Practice (GMP) certification and zero product recalls could be accepted. This shows that quality management has become an integral part of B2B contract evaluation.

### 2. Complaint management builds confidence

The hospitals praised the company's rapid response to product-related issues. Each report was handled through a documented Corrective and Preventive Action (CAPA) procedure and communicated transparently to the hospital's pharmacy unit. This responsiveness not only resolved problems quickly but also reinforced the perception that the supplier was reliable and professional.

### 3. Transparency and audit cooperation

Both hospitals emphasized that transparency during audits was a key factor in sustaining trust. The company allowed hospital representatives to visit the production site and review audit documents. This open-access policy strengthened the perception that the company had nothing to hide, thus increasing credibility.

### 4. Marketing communication integrated with quality performance

Marketing presentations included real data from quality control reports — such as complaint ratios, delivery punctuality, and audit results — which helped hospitals make objective procurement decisions. By using evidence rather than persuasion, the marketing team positioned the company as a trusted, data-driven partner.

### 5. Long-term business impact

These quality-based B2B practices resulted in measurable business growth. During the last three years, the company recorded a 25% increase in contract renewals and 20% growth in

hospital partnerships, proving that quality-driven trust translates into long-term profitability and market expansion.

In summary, the field findings demonstrate that a robust quality management system functions as a strategic trust-building mechanism that enhances competitiveness and ensures sustainable relationships with institutional partners.

#### 4.5 Discussion Summary

The discussion reveals that pharmaceutical quality management is not only a compliance requirement but also a strategic marketing asset in Business-to-Business (B2B) relationships. From the findings, three major insights can be summarized:

**1. Quality Creates Trust**

Consistent quality performance—demonstrated through GMP adherence, minimal complaints, and transparent documentation—builds strong institutional trust. Hospitals and distributors feel more secure when working with a company that upholds strict quality standards.

**2. Trust Strengthens Loyalty**

Once trust is established, healthcare institutions tend to maintain long-term partnerships, even if competitors offer lower prices. This loyalty reduces marketing costs and ensures business stability.

**3. Quality as a Competitive Advantage**

When quality metrics are communicated effectively, they become differentiating factors in tenders and B2B negotiations. Instead of competing on price, the company competes on reliability and reputation.

In summary, the discussion confirms that quality management in the pharmaceutical industry functions as both a technical and relational strategy. It ensures regulatory compliance while simultaneously acting as a trust-building mechanism that enhances business sustainability.

### CONCLUSION AND SUGGESTIONS

#### 5.1 Conclusion

Based on the findings and discussion, several key conclusions can be drawn:

**1. Quality management is a critical determinant of success in B2B pharmaceutical marketing.**

Consistent application of GMP, ISO standards, and quality assurance practices strengthens institutional trust and shapes the company's image as a reliable partner.

**2. Trust functions as a mediator between quality and long-term business relationships.**

Hospitals and distributors prioritize suppliers that demonstrate integrity, transparency, and responsiveness to quality-related issues.

**3. Integration of quality and marketing departments enhances credibility.**

When marketing communicates real data from quality assurance, business proposals become more persuasive and fact-based, improving the likelihood of contract renewal.

**4. Quality-oriented marketing increases competitiveness and sustainability.**

Pharmaceutical companies that position quality as their main differentiator achieve greater customer retention and long-term profitability.

In summary, quality management serves as both a technical and relational tool. It ensures compliance, fosters trust, and creates a foundation for sustained business growth in the pharmaceutical B2B market.

#### 5.2 Suggestions

Based on the conclusions, several recommendations are proposed:

**1. For pharmaceutical companies:**

Continue to strengthen integration between the Quality Assurance and Marketing divisions. Utilize quality performance data (audit results, complaint ratios, product stability data) as part of B2B marketing strategies.

**2. For healthcare institutions:**

Prioritize suppliers that maintain transparent quality management and are willing to cooperate in audits. This reduces procurement risks and ensures patient safety.

**3. For regulators and policymakers:**

Encourage the development of quality-based competition within the pharmaceutical industry through incentives for companies with strong GMP and ISO compliance records.

**4. For future research:**

Further studies could examine the quantitative relationship between specific quality indicators (such as complaint rates or audit scores) and partner loyalty levels in B2B contexts.

## REFERENCES

Deming, W. E. (1986). *Out of the Crisis*. MIT Press.

Juran, J. M. (2019). *Juran's Quality Handbook: The Complete Guide to Performance Excellence*. McGraw-Hill.

Kotler, P., & Keller, K. L. (2020). *Marketing Management* (15th ed.). Pearson Education.

Miles, M. B., & Huberman, A. M. (1994). *Qualitative Data Analysis*. Sage Publications.

Rahmawati, D. (2022). The Effect of Product Quality and Trust on Customer Loyalty in the Pharmaceutical Sector. *Journal of Health Management Studies*, 14(2), 101–112.

WHO (2021). *Good Manufacturing Practices for Pharmaceutical Products: Main Principles*. World Health Organization.